Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication

Rachel Morell; Jackie Curtis; Andrew Watkins; Josephine Poole; Hamish Fibbins; Elisa Rossimel; Mark Gerrard; Annette White; Scott Teasdale; Philip B Ward; Julia Lappin

doi:10.1016/j.psychres.2019.112606

Back

Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication

Journal article

Peer reviewed

Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication

Rachel Morell, Jackie Curtis, Andrew Watkins, Josephine Poole, Hamish Fibbins, Elisa Rossimel, Mark Gerrard, Annette White, Scott Teasdale, Philip B Ward, …

Psychiatry Research, Vol.281, pp.1-7

2019

DOI: https://doi.org/10.1016/j.psychres.2019.112606

PMID: 31629301

Files and links (1)

url

https://doi.org/10.1016/j.psychres.2019.112606View

Published Version

Abstract

Severe mental illness

Metabolic syndrome

Physical health

People living with severe mental illness (SMI) experience significant physical health co-morbidity. Few studies have focused on physical health outcomes for those prescribed long-acting injectable (LAI) antipsychotics. This observational cross-sectional study aimed to assess the prevalence of metabolic syndrome (MetS) and other cardio-metabolic risk factors in a large cohort prescribed LAI and managed by community mental health services. For participants with elevated cardio-metabolic risk factors, the proportion receiving appropriate management was assessed. Of the 301 eligible participants, many met the full criteria for MetS (44%) and its components. Cardio-metabolic risk factors were largely under- or un-treated. Smoking rates were very high (62%) along with reported high rates of physical inactivity and poor dietary intake. The vast majority (89%) reported seeing their general practitioner in the preceding twelve months. Individuals prescribed LAI have a very high prevalence of MetS and potentially modifiable risk factors for cardiovascular disease. Routine monitoring accompanied by evidence-based treatment of cardiometabolic abnormalities which contribute to significant morbidity, disability and premature death should be prioritised. Better collaboration between mental health services and primary care providers should be pursued to optimise the delivery of effective physical health care to individuals living with SMI.

Details

Title: Cardio-metabolic risk in individuals prescribed long-acting injectable antipsychotic medication
Authors: Rachel Morell (Author) - UNSW Australia
Jackie Curtis (Author) - UNSW Australia
Andrew Watkins (Author) - South Eastern Sydney Local Health District
Josephine Poole (Author) - South Eastern Sydney Local Health District
Hamish Fibbins (Author) - UNSW Australia
Elisa Rossimel (Author) - South Eastern Sydney Local Health District
Mark Gerrard (Author) - South Eastern Sydney Local Health District
Annette White (Author) - South Eastern Sydney Local Health District
Scott Teasdale (Author) - UNSW Australia
Philip B Ward (Author) - UNSW Australia
Julia Lappin (Author) - UNSW Australia
Publication details: Psychiatry Research, Vol.281, pp.1-7
Publisher: Elsevier Ireland Ltd.
DOI: 10.1016/j.psychres.2019.112606
ISSN: 1872-7123
PMID: 31629301
Organisation Unit: University of the Sunshine Coast, Queensland; Thompson Institute
Language: English
Record Identifier: 99498407102621
Output Type: Journal article

Metrics

12 Record Views

15 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Web Of Science research areas: Psychiatry

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites